NCT04323956 2026-02-02Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaMayo ClinicPhase 1 Active not recruiting50 enrolled
NCT03220022 2025-07-18Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasNational Cancer Institute (NCI)Phase 1 Active not recruiting46 enrolled